Analysts predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will post ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Oxford Immunotec Global PLC’s earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.23). Oxford Immunotec Global PLC reported earnings per share of ($0.22) in the same quarter last year, which suggests a negative year-over-year growth rate of 54.5%. The business is expected to report its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full-year earnings of ($2.11) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($2.00). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.07) to ($0.75). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Oxford Immunotec Global PLC.
OXFD has been the subject of several research reports. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, August 30th. BTIG Research set a $21.00 price target on Oxford Immunotec Global PLC and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Cowen and Company reaffirmed a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. Robert W. Baird reaffirmed a “buy” rating and issued a $20.00 price target on shares of Oxford Immunotec Global PLC in a research note on Wednesday, November 1st. Finally, ValuEngine downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $19.75.
TRADEMARK VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/11/12/zacks-analysts-expect-oxford-immunotec-global-plc-oxfd-will-announce-earnings-of-0-34-per-share.html.
Oxford Immunotec Global PLC (NASDAQ OXFD) opened at $12.94 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global PLC has a 52-week low of $12.19 and a 52-week high of $19.51.
In other Oxford Immunotec Global PLC news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now directly owns 17,778 shares of the company’s stock, valued at $237,336.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Edwardson sold 9,739 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $16.14, for a total value of $157,187.46. Following the completion of the transaction, the chief operating officer now directly owns 92,905 shares in the company, valued at $1,499,486.70. The disclosure for this sale can be found here. Insiders sold 70,739 shares of company stock worth $1,167,597 over the last three months. Insiders own 8.11% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Parkwood LLC lifted its position in shares of Oxford Immunotec Global PLC by 12.9% during the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after buying an additional 1,465 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of Oxford Immunotec Global PLC by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after buying an additional 1,845 shares in the last quarter. American International Group Inc. raised its stake in Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after purchasing an additional 904 shares during the period. Alliancebernstein L.P. bought a new stake in Oxford Immunotec Global PLC during the 2nd quarter valued at approximately $247,000. Finally, Asymmetry Capital Management L.P. bought a new stake in Oxford Immunotec Global PLC during the 2nd quarter valued at approximately $273,000. 78.77% of the stock is currently owned by hedge funds and other institutional investors.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.